MaticaBio Hires Executive from Global Company to "Strengthen Order Acquisition Capabilities"

"Strengthening CGT Contract Development and Manufacturing Capabilities"

Matica Biotech, the U.S. subsidiary of Cha Biotech, announced on the 19th that it has recruited new executives. Through this, the company plans to strengthen its contract development and manufacturing organization (CDMO) capabilities for cell and gene therapies (CGT).

Laura Parks, Vice President of Sales at Matica Biotechnology (left), and Heather Sugru, Executive Director of Partnership Management.
[Photo by Cha Biotech]

Matica Biotech has appointed Laura Parks as Vice President of Sales and Heather Sugrue as Executive Director of Partnership Management.

Laura Parks is a business development and sales strategy expert who has led marketing and commercialization strategies at global bio companies for over 20 years, including serving as President of the Finished Products Division at the global pharmaceutical company DSM and as Head of Sales and Strategy at the global CDMO company Patheon.

Heather Sugrue managed the Cell and Gene Services team as North American Sales Development Manager at the global CDMO company Catalent. She has led business development and global contract sales as Vice President of Sales, Vice President of Management, and Business Development Advisor at global bio companies including CRO company Syngene and Patheon.

Yoonjung Song, CEO of Matica Biotech, said, "Once the construction of the second plant currently underway locally is completed, CDMO production capacity will expand fourfold from 500ℓ to 2000ℓ. We plan to actively pursue contract orders together with Vice President Laura Parks and Executive Director Heather Sugrue, who have diverse work experience at global bio and CDMO companies."

Cha Biotech established Matica Biotech to enter the U.S. CGT CDMO market. Last year, it became the only Korean company to complete a CGT CDMO facility in College Station, Texas. The facility produces viral vectors such as lentivirus vectors and adeno-associated virus vectors, which are key raw materials for CGT. In June, it also developed its own cell line called 'Matimax.'

Matica Biotech plans to continuously expand its contract orders while securing CDMO-related process technologies and expanding its business scope to include the production of viral vectors as well as various cell therapies.

This content was produced with the assistance of AI translation services.